Produkt der Woche

JANUS® G3 Automation Workstations
Vergrößern

PerkinElmer

JANUS® G3 Automation Workstations

JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation with a choice of pipetting heads, gripper options, and application accessories for complete, walk-away automation. JANUS G3 WinPREP user friendly software with Application Assistant interface provides “drag-and-drop” applications programming without complexity.

The JANUS instrument family includes four workstations, the Mini, Standard, Integrator, and Expanded platforms, providing complete flexibility to best suit your particular application and deck capacity requirements; additionally, NGS and Biotherapeutics application specific workstations designed with customer input for optimal automated NGS library preparation and small scale purification, respectively.

Find out more at www.perkinelmer.co.uk/automated-liquid-handling

none

Products

CANDOR

ReadyTector is an easy, quick and clear all-in-one detection solution for Western blotting.

Candor Bioscience GmbH

All-in-one solution for Western blots

The one-step solution contains all ingredients for quick immunodetection. Only a specific primary antibody has to be added. “All-in-one” stands for all ingredients in one solution as well as for all-in-one step. Blocking and binding of primary and secondary antibodies are carried out simultaneously. 

The only additional step is washing with the specific ReadyTector Wash Buffer.

ReadyTector for Western blotting is easy, quick and clear:

  • easy – very simple procedure
  • quick – very fast procedure with very quick results
  • clear – no background

The ReadyTector kit contains the all-in-one Solution and the Wash Buffer. Bottle sizes of 40 ml, 120 ml and 500 ml are available.


Contact:

Candor Bioscience GmbH

Simoniusstrasse 39

88239 Wangen, Germany

Tel.: +49(0)-7522-7952-70

Fax: +49(0)-7522-7952-729

info[at]readytector.com

www.readytector.com

Life Technologies

SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs.

Life Technologies

SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. It is ideal for RT-PCR of a specific gene or for generating cDNA from total or poly (A)+ RNA samples. Like SuperScript® II, it synthesizes a complementary DNA strand from single-stranded RNA, DNA, or from an RNA:DNA hybrid. SuperScript® III RT is genetically engineered by the introduction of point mutations that increase half-life, reduce RNase activity, and increase thermal stability. SuperScript® III RT features:

  • Thermostability—half-life of 220 min at 50°C
  • Yield—reduced RNase H activity for more full-length cDNA
  • Specificity—full activity at 50°C for increased specificity with gene-specific primers
  • Applications—array labeling, cDNA libraries, RT-PCR, primer extension, 3´ and 5´ RACE

For further information please click here.

TAP Biosystems

TAP Biosystems installs CellBase CT system at PrimeCell to provide multiple Autologous Cell Therapies.

TAP Biosystems

TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, is pleased to announce it is installing a system to automate the ex-vivo expansion of autologous cell therapies (CellBase CT™) at Czech-based firm PrimeCell, one of Central and Eastern Europe’s largest regenerative medicine companies.

The CellBase CT system at PrimeCell will be used in their new GMP facility at the National Tissue Centre Inc to rapidly scale up their manual cell culture processes in T-flasks and will provide a fully-contained aseptic cell expansion area. This will allow scientists to manufacture multiple autologous cell therapies from many individual patients in parallel and will enable the company to supply clients, including regional transplant centres in the Czech Republic, with a range of clean autologous therapies.

Dr Ralph von Strandmann, TAP Biosystems' European Sales Manager stated: “With EU funding for new technologies, there has been an increasing interest in manufacturing biotechnology products in Central and Eastern Europe. This has led progressive companies here to realise that utilising efficient methods of manufacturing cell therapies will provide them with a significant advantage in this competitive sector.”

Dr. von Strandmann added: “We are pleased that PrimeCell will be using CellBase CT to automate expansion of their autologous stem cell therapies.  It is an excellent, cost-efficient alternative to labour intensive manual cell culture and could help make autologous cell therapies less expensive and more widely accessible to patients in Central and Eastern Europe.”

Contact:

TAP Biosystems

Matthew Walker

Head of Communications

York Way, Royston

Hertfordshire, SG8 5WY, UK

Tel: +44 (0) 1763 227200

Fax: +44 (0) 1763-227201

matthew.walker[at]tapbiosystems.com

www.tapbiosystems.com

PROMEGA

The Nano-Glo® Dual-Luciferase® Reporter (NanoDLR) Assay allows you to detect the activities of firefly and NanoLuc® luciferases in a single sample.

Promega Corporation

The Nano-Glo® Dual-Luciferase® Reporter (NanoDLR) Assay allows you to detect the activities of firefly and NanoLuc® luciferases in a single sample. Improved firefly chemistry and the bright, sensitive NanoLuc® luciferase make this a highly sensitive dual assay that is simple to use, provides superior data quality, and allows greater flexibility in assay design.

In the Nano-Glo® Dual-Luciferase® Reporter Assay, firefly luciferase activity is measured first using the ONE-Glo™ EX Luciferase Assay Reagent. NanoDLR™ Stop & Glo® Reagent is then added to quench the firefly signal and provide the substrate needed to measure NanoLuc® luciferase activity. The signal half-life is greater than two hours for both reporters.

HEK293 cells transfected with a 1:1:8 ratio of either TK-Rluc (Renilla):TK-Fluc (firefly):carrier DNA or TK-Nluc (NanoLuc):TK-Fluc:carrier DNA and assayed with NanoDLR™, DLR™ or Dual-Glo® Dual-Luciferase Assay System as indicated.  When luciferases are expressed from the same promoter, the NanoDLR™ Assay provides bright signal for both Fluc and Nluc reporters with stable "glow-type" signals.

Potent inhibition of firefly luciferase (Fluc) provides excellent signal separation, allowing accurate measurement of even low amounts of NanoLuc® luciferase (Nluc), even in the presence of high Fluc activity.

Even extremely high Fluc signals are reduced to near background levels by NanoDLR™ Stop & Glo® Reagent, providing excellent signal separation and low variability without sacrificing the sensitivity of two bright luminescent readouts.

For mor information please click here.


Contact:

Promega GmbH

Dr. Anette Schwenzer

Schildkrötstr. 15

68199 Mannheim

Tel.: +49 621 8501-110

anette.schwenzer@promega.com

www.promega.com 

Biological Industries

Isolate, grow, maintain and differentiate human mesenchymal stem cells from various sources with a complete, optimized culture system.

Biological Industries

Biological Industries offers a full product portfolio, including stem cell culture media, freezing media, attachment solution, cell dissociation solutions and initial differentiation kits. 

Isolation and Culture

MSC NutriStem® XF line and its supporting reagents are optimized for human mesenchymal stem cells from a variety of tissue sources and promise optimal growth and maintenance of hMSC, high proliferation rate, superior maintenance of cell characteristics, fibroblast-like morphology maintenance and long-term growth

Differentiation

MSC GoTM Osteogenic, Adipogenic and Chondrogenic  XF series offer a complete system for the evaluation and  reliable induction of hMSC from various sources into adipocytes, chondrocytes and osteoblasts/osteocytes. The kits are designed to be user friendly with all the growth factors and supplements necessary for the direct differentiation of hMSC

All products are completely free of serum and non-human derived components, hence:

  • Eliminate contagious health risks from viral agents, mycoplasma, and prions
  • Eliminate lot-to-lot variability
  • Limit immunological reactions once cells are transplanted
  • Suitable for clinical applications
  • Ensure reliable performance
  • Eliminate the drawbacks of unwanted background differentiation and interruption in the cell metabolism 


For more details please visit: www.bioind.com/mesenchymal-stem-cells

Or contact us: info[at]bioind.com

AMSBIO

AMSBIO announces the launch of mRNA-In™ and mRNA-In™ Neuro – a new range of high efficiency, targeted transfection reagents.

AMS Biotechnology (AMSBIO)

Offering high transfection efficiency and expression levels across a broad range of cell types, including stem cells and primary cells, mRNA-In™ is a robust and easy-to-use mRNA delivery solution proven in applications including protein expression and iPSC-reprogramming. Recognized as among the most difficult cell types to transfect, either freshly isolated or cryopreserved neurons or neural stem cells can be transfected with exceptionally low cytotoxicity using the specifically designed and optimized  mRNA-In™ Neuro reagent.

AMSBIO’s new mRNA-In™ transfection reagents require very low amounts of mRNA to achieve maximum transfection efficiency. Moreover, mRNA expression levels can be adjusted by just changing the amount of mRNA transfection thereby significantly minimizing unintended off-target immune activation. Across a wide range of cell types, mRNA-In™ reagents have been shown to produce exceptionally high transfection efficiency while maintaining optimal cell health and viability. 

Messenger RNA (mRNA) delivery has become a widely used non-viral gene delivery technique due to the significant advantages it offers. This includes almost no risk of integration into the host genome, which can lead to insertional mutagenesis and activation of oncogenes, and the ability to achieve very high transfection efficiencies nearing that of viral delivery methods. Also by contrast with DNA transfection, mRNA delivery does not enter the nucleus, rather only cytosolic delivery is required, resulting in more a rapid expression method.

Comprising a proprietary formulation of chemically defined and animal-free compounds mRNA-In™ transfection reagents are the latest addition to a growing range of nucleic acid delivery solutions from AMSBIO optimized for superior transfection efficiency and maximum cell viability.

For further information please visit www.amsbio.com/mRNA-transfection-reagent.aspx or contact AMSBIO now on +44-1235-828200 / +1-617-945-5033 or email info[at]amsbio.com.


Worldwide HQ:

AMS Biotechnology (AMSBIO)

184 Milton Park

Abingdon 

Oxon OX14 4SE

UK

Tel: +44-1235-828200

Fax: +44-1235-820482

Email: info[at]amsbio.com 

Web: www.amsbio.com

SARTORIUS

Sartorius Stedim Biotech presents the new system FlexAct® that enables you to custom- configure single-use solutions for entire biomanufacturing steps.

Sartorius Stedim Biotech

FlexAct® is a new system that enables you to custom- configure single-use solutions for entire biomanufacturing steps. The FlexAct® system consists of the central opera- ting module that offers the widest variety of configuration options so you can take complete control of practically any steps in upstream and downstream processing.

Sartorius Stedim Biotech presents the FlexAct® BP for buffer preparation. Next in line are media preparation (MP), cell harvest (CH), UF | DF crossflow (UD), virus removal (Vr), virus inactivation (VI), polishing (PO), form | fill (FF) and form | transfer (FT).

The core of FlexAct®, the central operating module (COM), has been designed to be used in any application. This means you can quickly reconfigure FlexAct® in just a few easy steps. For example, take the FlexAct® BP for buffer preparation and effortlessly convert it into FlexAct® VR for virus removal.

And it goes without saying that the technologies and products used in FlexAct® are scalable. This makes FlexAct® a future-proof system in every respect; one that gives you the greatest possible flexibility.


Contact:

Dominic Grone

Group Corporate Communications

Sartorius AG

Goettingen

Phone:+49.(0)551.308.3324

email: dominic.grone[at]sartorius.com

web: www.sartorius.com

Pall

The Cadence Inline Concentrator simplifies concentrating solutions of biomolecules to an in-line, single-use, ready-to-use process.

PALL

The recirculation loop associated with tangential flow filtration (TFF) conventionally used for this process is eliminated. Pump and tube sizes are reduced, product recovery is maximized, and sensitive proteins are exposed to less shear. The Cadence Single-Use Inline Concentrator moves the product being processed through a proprietary design flow path in a pre-assembled module with all connections already in place and designed to couple to available standard tubing manifolds.

Typical applications include monoclonal antibodies, fractionated antibodies, recombinant proteins, other proteins and recombinant blood factors. The Cadence Single-Use Inline Concentrator is used to concentrate clarified bulk after fermentation, and to reduce the number or size of bags needed and increase product concentration to improve chromatography performance. 

Cost projections with BioSolve software show that, compared to conventional single-use TFF, the Cadence Single-Use Inline Concentrator provides a 31% cost of goods sold and a 66% capital investment savings per batch because of the elimination of the need for intermediate tanks, ability to use smaller chromatography columns, energy savings, and the ability to couple processes to reduce downtime.


For further information please click here.

DRIFTON

This is a highly advanced programmable pneumatic digital dispenser. It can store eight programmes and it can partially compensate for viscosity variation.

Drifton

The dispenser features new digital controller technology with a clear digital display for a simultaneous overview of all parameters.

The Drifton 206-DF dispenser can store eight programmes in the controller’s memory and when it is programmed, it will adjust the pneumatic pressure automatically as the liquid becomes thicker or thinner.

The dispenser can partially compensate for variation in the dispensed medium.

Remember to order an air fitting to go with this one-component dispenser.

Contact:

Drifton A/S
Avedøreholmen 84
DK-2650 Hvidovre
Tel.: +45 3679 0000
E-mail: info[at]drifton.dk 

Sartorius

Thanks to the intuitive user interface, operating the BIOSTAT® A is ideal for beginners, reduces operating errors and speeds up training.

Sartorius

Operation using a tablet or smartphone is a mode offered in the Advanced package and enables you to monitor and control the BIOSTAT® A on the move – in the laboratory, in the office or even at home.

Download the brochure: BIOSTAT® A - Your professional start in cell cultivation and microbial fermentation (3.5 MB) 

Contact: 

Dominic Grone

Sartorius Corporate Administration GmbH

Group Corporate Communications

Weender Landstraße 94-108

37075 Goettingen

Germany

Tel.: +49.(0)551-308.3324

Fax: +49.(0)551-308.3410

e-mail: dominic.grone[at]sartorius.com

Visit us: www.sartorius.com

Vorherige Seite3/12Nächste Seite

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/service/products/pos/3.html?cHash=c3445b0e00e893d87196d710ffbc00ad&sort=desc

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%

FLOP

  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%

TOP

  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%

FLOP

  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)33.00 SEK1975.5%
  • NICOX (F)9.62 EUR428.6%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%

FLOP

  • BB BIOTECH (D)44.83 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.80 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 30.07.2016

Events

All Events

Partner-Events